313 results
8-K
EX-99.1
FOLD
Amicus Therapeutics Inc
9 May 24
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
7:00am
contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical
8-K
EX-99.2
FOLD
Amicus Therapeutics Inc
9 May 24
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
7:00am
This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical
8-K
EX-99.1
tfrj6igp
28 Feb 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
7:02am
8-K
EX-99.2
3kybhzh 1mi
28 Feb 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
7:02am
8-K
EX-99.1
41nqi
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
8-K
EX-99.2
9u59v0pwf
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
S-3ASR
gsa tqd5op
8 Nov 23
Automatic shelf registration
5:25pm
8-K
EX-99.2
nhmc jqtc5
8 Nov 23
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-99.1
vbbl8ahj52fkfxzp5
8 Nov 23
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-99.1
2vodh1 6atn2
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
8uo77rksjd2ogrp
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-10.1
7ne0ed qvaieunwvuk8l
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-10.2
hod 835c40r10s
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-99.1
uon2xq3
28 Sep 23
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
12:00pm
8-K
EX-99.2
q3z 89dea
28 Sep 23
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
12:00pm